What are the primary pharmacological differences and side effect profiles of the newest FDA-approved orexin receptor antagonists compared to traditional benzodiazepine receptor agonists for chronic insomnia?
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
What are the primary pharmacological differences and side effect profiles of the newest FDA-approved orexin receptor antagonists compared to traditional benzodiazepine receptor agonists for chronic insomnia?
3 real searches · 1 real-search pass
FDA approved dual orexin receptor antagonists daridorexant lemborexant suvorexant prescribing information mechanism adverse reactions chronic insomnia comparison benzodiazepinesGoogle ↗
OBSERVED
FDA prescribing information Quviviq Dayvigo Belsomra boxed warnings adverse reactions sleep paralysis cataplexy complex sleep behaviorsGoogle ↗
OBSERVED
AASM clinical practice guideline pharmacologic treatment chronic insomnia orexin receptor antagonists benzodiazepine receptor agonists evidenceGoogle ↗
OBSERVED
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
Classifying 3 queries…
Searches and sources
ChatGPT3 real searches · gpt-6
FDA approved dual orexin receptor antagonists daridorexant lemborexant suvorexant prescribing information mechanism adverse reactions chronic insomnia comparison benzodiazepines Google ↗
FDA prescribing information Quviviq Dayvigo Belsomra boxed warnings adverse reactions sleep paralysis cataplexy complex sleep behaviors Google ↗
AASM clinical practice guideline pharmacologic treatment chronic insomnia orexin receptor antagonists benzodiazepine receptor agonists evidence Google ↗
- Review · accessdata.fda.gov
- Other Review(s) · accessdata.fda.gov
- These highlights do not include all the information needed to use QUVIVIQ safely and effectively. See full prescribing information for QUVIVIQ. QUVIVIQ (daridorexant) tablets, for oral use, CIV Initial U.S. Approval: 2022 · dailymed-us-east-1.awsprod.nlm.nih.gov
- Current and novel dual orexin receptor antagonists for the treatment of insomnia: the emergence of vornorexant | International Journal of Neuropsychopharmacology · academic.oup.com
- Combination treatment for chronic insomnia disorder in adults: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment · pmc.ncbi.nlm.nih.gov
- Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. · escholarship.org
- These highlights do not include all the information needed to use QUVIVIQ safely and effectively. See full prescribing information for QUVIVIQ. QUVIVIQ (daridorexant) tablets, for oral use, CIV Initial U.S. Approval: 2022 · dailymed.nlm.nih.gov
- DailyMed · dailymed-us-east-1.awsprod.nlm.nih.gov
- 2025 VA/DoD Chronic Insomnia & Obstructive Sleep Apnea Clinical Guideline - Guideline Summary · guidelinecentral.com
- The Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea (Insomnia/OSA) (2025) · healthquality.va.gov
Queries
3 queries · click a column to sort
| Query / type | Search | Intent | Query class | Routing format | Cluster | Freq ↓ | Weight |
|---|---|---|---|---|---|---|---|
FDA approved dual orexin receptor antagonists daridorexant lemborexant suvorexant prescribing information mechanism adverse reactions chronic insomnia comparison benzodiazepines OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
FDA prescribing information Quviviq Dayvigo Belsomra boxed warnings adverse reactions sleep paralysis cataplexy complex sleep behaviors OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
AASM clinical practice guideline pharmacologic treatment chronic insomnia orexin receptor antagonists benzodiazepine receptor agonists evidence OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 |